6.1.1.10: methionine-tRNA ligase
This is an abbreviated version!
For detailed information about methionine-tRNA ligase, go to the full flat file.
Word Map on EC 6.1.1.10
-
6.1.1.10
-
synthetases
-
aminoacyl-trna
-
aminoacylation
-
anticodons
-
homocysteine
-
trnafmet
-
thiolactone
-
aarss
-
isoleucyl-trna
-
trypsin-modified
-
isoleucylation
-
noncognate
-
tyrosyl-trna
-
arc1p
-
atp-ppi
-
formylmethionine
-
medicine
-
leucyl-trna
-
kmsks
-
misacylation
-
hcy-thiolactone
-
ilers
-
lysyl-trna
-
trna-binding
-
valrs
-
valyl-trna
-
cysteinyl-trna
-
drug development
-
pharmacology
- 6.1.1.10
- synthetases
- aminoacyl-trna
- aminoacylation
-
anticodons
- homocysteine
- trnafmet
-
thiolactone
-
aarss
-
isoleucyl-trna
-
trypsin-modified
-
isoleucylation
-
noncognate
- tyrosyl-trna
- arc1p
-
atp-ppi
- formylmethionine
- medicine
- leucyl-trna
-
kmsks
-
misacylation
-
hcy-thiolactone
- ilers
- lysyl-trna
-
trna-binding
- valrs
- valyl-trna
-
cysteinyl-trna
- drug development
- pharmacology
Reaction
Synonyms
hcMetRS, hmMetRS, let-65, MARS, mars-1, MetG, Methionine translase, Methionine--tRNA ligase, Methionyl tRNA synthetase, Methionyl-transfer ribonucleate synthetase, Methionyl-transfer ribonucleic acid synthetase, Methionyl-transfer RNA synthetase, methionyl-tRNA synthetase, methionyl-tRNA synthetase1, methionyl-tRNA-synthetase, MetRS, MetRS1, MetRS2, MetS, More, MRS, MRSapi, MRScyt, Synthetase, methionyl-transfer ribonucleate
ECTree
Advanced search results
Application
Application on EC 6.1.1.10 - methionine-tRNA ligase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
-
parasite MetRS is an attractive drug target due to its essential role in protein synthesis and cell survival. Comparative sequence analysis discloses differences between the trypanosome and mammalian methionyl-tRNA synthetases
medicine
-
REP3123 is a fully synthetic methionyl-tRNA synthase inhibitor in pre-clinical development as a novel agent to treat Clostridium difficile infection, CDI
medicine
-
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug
medicine
-
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug
medicine
-
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug
medicine
-
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug
medicine
-
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug
medicine
-
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug to combat Clostridium difficile infections
medicine
-
REP8839 is a selective inhibitor of methionyl-tRNA synthetase with antibacterial activity against a variety of gram-positive organisms
medicine
-
REP8839 is a selective inhibitor of methionyl-tRNA synthetase with antibacterial activity against a variety of gram-positive organisms
medicine
-
REP8839 is a selective inhibitor of methionyl-tRNA synthetase with antibacterial activity against a variety of gram-positive organisms
medicine
-
REP8839 is a selective inhibitor of methionyl-tRNA synthetase with antibacterial activity against a variety of gram-positive organisms
medicine
-
REP8839 is a selective inhibitor of methionyl-tRNA synthetase with antibacterial activity against a variety of gram-positive organisms
medicine
-
methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer